Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer

Figure 1 Representative 1. 5T magnetic resonance imaging/magnetic resonance spectroscopic imaging in a 58-year-old patient with prostate specific antigen 96.53 ng/mL, clinical stage T3 and surgical Gleason score 4 + 5. A: Axial T2-weighted image and overlaid point-resolved spectroscopic box indicating excitation region selected and 3D MRSI demonstrating three suspicious voxels marked with asterisks; B: ¹⁸F-FDG-PET/CT fusion image shows a focal uptake in the left prostate; C: Whole-mount step-section histopathology after radical prostatectomy shows a large cancer in the left prostate. MRSI: Magnetic resonance spectroscopic imaging; ¹⁸F-FDG-PET/CT: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography.